Dyadic to Present at H.C. Wainwright Global Investment Conference

by B2i | May 20, 2022 | Press Releases

JUPITER, Fla., May 20, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform...

Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments

by B2i | May 12, 2022 | Press Releases

New research, license, and collaboration agreement with a Global Food Ingredients Company using Dyadic’s proprietary biotechnologiesLicense agreement with Phibro/Abic Animal Health to develop and commercialize animal vaccine(s)Advancing first-in-human clinical...

Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients

by B2i | May 11, 2022 | Press Releases

JUPITER, Fla., May 11, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and...

Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”

by B2i | May 9, 2022 | Press Releases

Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100, recombinant protein receptor binding domain (RBD)...

Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

by B2i | Apr 28, 2022 | Press Releases

JUPITER, Fla., April 28, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...